BDRX
Price
$1.88Alerts
Change
-$0.14 (-6.93%)
Updated
Nov 20 closing price
Capitalization
2.54M
Intraday BUY SELL Signals
SCNI
Price
$1.58Alerts
Change
+$0.03 (+1.94%)
Updated
Nov 20 closing price
Capitalization
298.81K
Intraday BUY SELL Signals
Interact to see
Advertisement

BDRX vs SCNI

BDRX vs SCNI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BDRX vs. SCNI commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDRX is a Hold and SCNI is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BDRX with price predictions
Nov 20, 2026

Momentum Indicator for BDRX turns negative, indicating new downward trend

BDRX saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 89 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for BDRX entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for BDRX just turned positive on October 15, 2026. Looking at past instances where BDRX's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.

Following a +12.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDRX advanced for three days, in 131 of 177 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.264) is normal, around the industry mean (3.596). P/E Ratio (-0.097) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (10.977) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. BDRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for SCNI with price predictions
Nov 20, 2026

SCNI in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026

SCNI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where SCNI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 62 of 83 cases where SCNI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

Following a +7.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCNI advanced for three days, in 149 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCNI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for SCNI entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.049) is normal, around the industry mean (3.596). P/E Ratio (0.016) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.536) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SCNI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCNI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BDRX vs SCNI: Fundamental Ratings
BDRX
SCNI
OUTLOOK RATING
1..100
510
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9712
PRICE GROWTH RATING
1..100
9597
P/E GROWTH RATING
1..100
6997
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCNI's Valuation (50) in the Pharmaceuticals Major industry is in the same range as BDRX (52) in the Biotechnology industry. This means that SCNI’s stock grew similarly to BDRX’s over the last 12 months.

SCNI's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BDRX (100) in the Biotechnology industry. This means that SCNI’s stock grew similarly to BDRX’s over the last 12 months.

SCNI's SMR Rating (12) in the Pharmaceuticals Major industry is significantly better than the same rating for BDRX (97) in the Biotechnology industry. This means that SCNI’s stock grew significantly faster than BDRX’s over the last 12 months.

BDRX's Price Growth Rating (95) in the Biotechnology industry is in the same range as SCNI (97) in the Pharmaceuticals Major industry. This means that BDRX’s stock grew similarly to SCNI’s over the last 12 months.

BDRX's P/E Growth Rating (69) in the Biotechnology industry is in the same range as SCNI (97) in the Pharmaceuticals Major industry. This means that BDRX’s stock grew similarly to SCNI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BDRXSCNI
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
MACD
ODDS (%)
Bullish Trend 6 days ago
79%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 25 days ago
74%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 5 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 22, 2026
Stock price -- (BDRX: $1.88 vs. SCNI: $1.58)
Brand notoriety: BDRX and SCNI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BDRX: 14% vs. SCNI: 22%
Market capitalization -- BDRX: $2.54M vs. SCNI: $298.81K
BDRX [@Biotechnology] is valued at $2.54M. SCNI’s [@Biotechnology] market capitalization is $298.81K. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BDRX’s FA Score shows that 0 FA rating(s) are green while SCNI’s FA Score has 1 green FA rating(s).

  • BDRX’s FA Score: 0 green, 5 red.
  • SCNI’s FA Score: 1 green, 4 red.
According to our system of comparison, SCNI is a better buy in the long-term than BDRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BDRX’s TA Score shows that 4 TA indicator(s) are bullish while SCNI’s TA Score has 4 bullish TA indicator(s).

  • BDRX’s TA Score: 4 bullish, 3 bearish.
  • SCNI’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, SCNI is a better buy in the short-term than BDRX.

Price Growth

BDRX (@Biotechnology) experienced а -21.99% price change this week, while SCNI (@Biotechnology) price change was -1.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.

Industries' Descriptions

@Biotechnology (-11.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

SCNI and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCNI has been closely correlated with TAOX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if SCNI jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCNI
1D Price
Change %
SCNI100%
+1.94%
TAOX - SCNI
73%
Closely correlated
-10.40%
MBIO - SCNI
37%
Loosely correlated
-4.30%
VANI - SCNI
32%
Poorly correlated
+4.59%
BDRX - SCNI
32%
Poorly correlated
-6.93%
BYSI - SCNI
32%
Poorly correlated
-24.49%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NSP48.381.10
+2.33%
Insperity
HNGE105.78-2.32
-2.15%
Hinge Health Inc.
RYAM4.61-0.28
-5.73%
Rayonier Advanced Materials
PCLA5.56-0.52
-8.55%
PicoCELA Inc.
SPRC0.20-0.11
-34.83%
SciSparc Ltd.